News Related to NKTR-255

Related coverage linked through entity extraction aliases.

Nektar Therapeutics Advances REZPEG to Phase 3, Strengthens Financial Position

Mar 14, 2026

Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.

Nektar Therapeutics Closes $460 Million Public Offering with Full Underwriter Exercise

Feb 14, 2026

Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.